XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating activities    
Net income including noncontrolling interests $ 1,490 $ 221,103
Less: income from discontinued operations 731 0
Income from continuing operations 759 221,103
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:    
Non-cash change in estimated fair value of contingent liabilities 2,595 4,976
Realized gain on sale of short-term investment (1,776) (1,988)
Gain on disposal of assets 183 0
Depreciation and amortization 8,322 1,940
Amortization of discount on investments, net 510 73
Amortization of debt discount and issuance fees 8,130 7,646
Stock-based compensation 13,690 9,511
Deferred income taxes 347 (191,615)
Accretion of note payable 0 16
Gain on deconsolidation of Viking Therapeutics 0 (28,190)
Change in fair value of the Viking convertible debt receivable and warrants (464) 0
Loss from Viking Therapeutics 14,139 3,040
Changes in operating assets and liabilities:    
Accounts receivable (411) 7,142
Inventory (2,394) (158)
Other current assets (9) (438)
Other long-term assets (31) (546)
Accounts payable and accrued liabilities (3,079) (4,993)
Restricted investments 0 661
Deferred revenue 1,497 (118)
Net cash provided by operating activities 42,008 28,062
Investing activities    
Purchase of commercial license rights (17,695) (4,030)
Payments to CVR holders and other contingency payments (7,055) (4,941)
Purchases of property and equipment (1,783) (27)
Cash paid for acquisition, net of cash acquired (92,504) 0
Purchase of short-term investments (73,109) (111,788)
Proceeds from sale of property and equipment 0 1
Proceeds received from repayment of Viking note receivable 300 0
Reduction of cash due to deconsolidation of Viking 0 (247)
Proceeds from sale of short-term investments 23,387 5,680
Proceeds from maturity of short-term investments 113,694 22,967
Net cash used in investing activities (56,465) (101,385)
Financing activities    
Net proceeds from stock option exercises and ESPP 4,608 7,379
Taxes paid related to net share settlement of equity awards (999) 0
Share repurchase (489)
Net cash provided by financing activities 3,609 6,890
Net decrease in cash and cash equivalents (10,848) (66,433)
Cash and cash equivalents at beginning of period 97,428 160,203
Cash and cash equivalents at end of period 86,580 93,770
Supplemental disclosure of cash flow information    
Interest paid 1,838 1,822
Taxes paid 36 19
Supplemental schedule of non-cash activity    
Stock issued for acquisition, net of issuance cost (77,330) 0
Unsettled repurchase of common stock (1,554) 0
Stock and warrant received for repayment of Viking notes receiveable 1,200 0
Accrued inventory purchases 0 0
Unrealized gain (loss) on AFS investments (271) 3,082
Purchase of Common Stock [Member]    
Investing activities    
Purchase of Viking common stock and warrants (1,000) 0
Viking Therapeutics, Inc.    
Investing activities    
Purchase of Viking common stock and warrants $ (700) $ (9,000)